Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages

Shares of Annovis Bio, Inc. (NYSE:ANVSGet Free Report) have been given an average recommendation of “Buy” by the six ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $33.60.

ANVS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Annovis Bio in a report on Tuesday, October 1st. EF Hutton Acquisition Co. I raised shares of Annovis Bio to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Rodman & Renshaw restated a “buy” rating and issued a $67.00 price objective on shares of Annovis Bio in a research report on Tuesday, July 2nd.

Get Our Latest Analysis on Annovis Bio

Institutional Trading of Annovis Bio

Several hedge funds have recently modified their holdings of the company. Cetera Advisors LLC bought a new position in Annovis Bio during the 1st quarter worth about $122,000. Greenwich Wealth Management LLC raised its stake in Annovis Bio by 19.9% in the 2nd quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares during the last quarter. XTX Topco Ltd purchased a new stake in Annovis Bio in the second quarter valued at approximately $115,000. Redmond Asset Management LLC raised its stake in shares of Annovis Bio by 6.1% during the 1st quarter. Redmond Asset Management LLC now owns 36,157 shares of the company’s stock valued at $430,000 after buying an additional 2,077 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Annovis Bio by 6.1% in the first quarter. Vanguard Group Inc. now owns 357,942 shares of the company’s stock valued at $4,260,000 after acquiring an additional 20,588 shares during the period. 15.83% of the stock is owned by hedge funds and other institutional investors.

Annovis Bio Stock Down 2.5 %

Shares of ANVS stock opened at $8.20 on Thursday. The firm has a market cap of $91.60 million, a P/E ratio of -1.43 and a beta of 1.72. The business has a 50-day moving average price of $8.52 and a two-hundred day moving average price of $8.84. Annovis Bio has a 12-month low of $4.53 and a 12-month high of $22.49.

Annovis Bio (NYSE:ANVSGet Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.19. As a group, research analysts expect that Annovis Bio will post -2.53 EPS for the current fiscal year.

Annovis Bio Company Profile

(Get Free Report

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.

Featured Stories

Analyst Recommendations for Annovis Bio (NYSE:ANVS)

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.